Wistedt 1984.

Methods	Allocation: randomisation list, blocks of six. Blindness: double. Duration: 20 weeks.
Participants	Diagnosis: schizophrenia (RDC). History: duration ill ‐ range 0‐12 yrs, informed consent given. N=51. Age range: 21‐63 yrs. Sex: 33 M, 18 F. Setting: 4 weeks in hospital, community thereafter, multicentre.
Interventions	1. Haloperidol decanoate: dose mean 122mg/injection, monthly. N=25. 2. Fluphenazine decanoate: dose mean 84mg/injection, monthly. N=26.*
Outcomes	Global impression (CGI). Mental state (CPRS). Leaving the study early. Additional medication. Side effects (AIMS, EPS). Unable to use ‐ Physiological measures (drug plasma levels ‐ non‐clinical outcomes, data not usable). Weight changes (non‐clincal outcomes, data not usable).
Notes	Dose ratio :1:1.4 (FD/HD).
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear